181 related articles for article (PubMed ID: 12210803)
1. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.
Dodel R; Hampel H; Depboylu C; Lin S; Gao F; Schock S; Jäckel S; Wei X; Buerger K; Höft C; Hemmer B; Möller HJ; Farlow M; Oertel WH; Sommer N; Du Y
Ann Neurol; 2002 Aug; 52(2):253-6. PubMed ID: 12210803
[TBL] [Abstract][Full Text] [Related]
2. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.
Relkin NR; Szabo P; Adamiak B; Burgut T; Monthe C; Lent RW; Younkin S; Younkin L; Schiff R; Weksler ME
Neurobiol Aging; 2009 Nov; 30(11):1728-36. PubMed ID: 18294736
[TBL] [Abstract][Full Text] [Related]
3. Natural human antibodies to amyloid beta peptide.
Szabo P; Relkin N; Weksler ME
Autoimmun Rev; 2008 Jun; 7(6):415-20. PubMed ID: 18558354
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin and Alzheimer's disease immunotherapy.
Solomon B
Curr Opin Mol Ther; 2007 Feb; 9(1):79-85. PubMed ID: 17330405
[TBL] [Abstract][Full Text] [Related]
5. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides.
Mruthinti S; Buccafusco JJ; Hill WD; Waller JL; Jackson TW; Zamrini EY; Schade RF
Neurobiol Aging; 2004 Sep; 25(8):1023-32. PubMed ID: 15212827
[TBL] [Abstract][Full Text] [Related]
6. Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations.
Klaver AC; Finke JM; Digambaranath J; Balasubramaniam M; Loeffler DA
Int Immunopharmacol; 2010 Jan; 10(1):115-9. PubMed ID: 19840873
[TBL] [Abstract][Full Text] [Related]
7. Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-beta.
Balakrishnan K; Andrei-Selmer LC; Selmer T; Bacher M; Dodel R
J Alzheimers Dis; 2010; 20(1):135-43. PubMed ID: 20164596
[TBL] [Abstract][Full Text] [Related]
8. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.
Boche D; Zotova E; Weller RO; Love S; Neal JW; Pickering RM; Wilkinson D; Holmes C; Nicoll JA
Brain; 2008 Dec; 131(Pt 12):3299-310. PubMed ID: 18953056
[TBL] [Abstract][Full Text] [Related]
9. Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1-40, (Abeta40), beta-amyloid 1-42 (Abeta42) and total Tau.
Stuerenburg HJ; Ganzer S; Müller-Thomsen T
Neuro Endocrinol Lett; 2005 Dec; 26(6):696-8. PubMed ID: 16380679
[TBL] [Abstract][Full Text] [Related]
10. The immune system, amyloid-beta peptide, and Alzheimer's disease.
Weksler ME; Gouras G; Relkin NR; Szabo P
Immunol Rev; 2005 Jun; 205():244-56. PubMed ID: 15882358
[TBL] [Abstract][Full Text] [Related]
11. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls.
Xu W; Kawarabayashi T; Matsubara E; Deguchi K; Murakami T; Harigaya Y; Ikeda M; Amari M; Kuwano R; Abe K; Shoji M
Brain Res; 2008 Jul; 1219():169-79. PubMed ID: 18534566
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides.
Bibl M; Esselmann H; Otto M; Lewczuk P; Cepek L; Rüther E; Kornhuber J; Wiltfang J
Electrophoresis; 2004 Sep; 25(17):2912-8. PubMed ID: 15349929
[TBL] [Abstract][Full Text] [Related]
13. Humoral immune response to fibrillar beta-amyloid peptide.
Miller DL; Currie JR; Mehta PD; Potempska A; Hwang YW; Wegiel J
Biochemistry; 2003 Oct; 42(40):11682-92. PubMed ID: 14529278
[TBL] [Abstract][Full Text] [Related]
14. Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease.
Morgan D; Gitter BD
Neurobiol Aging; 2004; 25(5):605-8. PubMed ID: 15172737
[TBL] [Abstract][Full Text] [Related]
15. Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice.
Sohn JH; So JO; Kim H; Nam EJ; Ha HJ; Kim YH; Mook-Jung I
Biochem Biophys Res Commun; 2007 Sep; 361(3):800-4. PubMed ID: 17678618
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
Rakover I; Arbel M; Solomon B
Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
[TBL] [Abstract][Full Text] [Related]
17. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses.
Chackerian B; Rangel M; Hunter Z; Peabody DS
Vaccine; 2006 Sep; 24(37-39):6321-31. PubMed ID: 16806604
[TBL] [Abstract][Full Text] [Related]
18. An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
Portelius E; Zetterberg H; Andreasson U; Brinkmalm G; Andreasen N; Wallin A; Westman-Brinkmalm A; Blennow K
Neurosci Lett; 2006 Dec; 409(3):215-9. PubMed ID: 17049739
[TBL] [Abstract][Full Text] [Related]
19. Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide.
Lue LF; Walker DG
J Neurosci Res; 2002 Nov; 70(4):599-610. PubMed ID: 12404514
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's Abeta vaccination of rhesus monkeys (Macaca mulatta).
Gandy S; DeMattos RB; Lemere CA; Heppner FL; Leverone J; Aguzzi A; Ershler WB; Dai J; Fraser P; St George Hyslop P; Holtzman DM; Walker LC; Keller ET
Mech Ageing Dev; 2004 Feb; 125(2):149-51. PubMed ID: 15037022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
